Categories AlphaGraphs, Earnings, Health Care
Earnings: Regeneron Pharmaceuticals (REGN) Q4 profit falls as revenues drop 31%
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Friday reported a sharp fall in fourth-quarter revenues and adjusted earnings.
Total revenues plunged 31% year-over-year to $3.41 billion in the three months ended December 2022. Excluding REGEN-COV and Ronapreve, however, revenues increased by 14%.
The biotechnology firm’s fourth-quarter adjusted earnings nearly halved to $12.56 per share from $23.42 per share in the same period of 2021. Unadjusted profit was $1.20 billion or $10.50 per share, compared to $2.23 billion or $19.69 per share last year.
“In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases, and our promising oncology and hematology assets,” said the company’s CEO Leonard Schleifer.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
